Flornaptitril PET Phase 3 (NCT06254469)
Overview
flowchart TD
clinical_trials_flornaptitril_["flornaptitril-pet-phase-3-nct06254469"]
style clinical_trials_flornaptitril_ fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_flor_0["Trial Details"]
clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_0
style clinical_trials_flor_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_flor_1["Study Arms"]
clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_1
style clinical_trials_flor_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_flor_2["Study Sites"]
clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_2
style clinical_trials_flor_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_flor_3["Background and Rationale"]
clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_3
style clinical_trials_flor_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_flor_4["Limitations of Current Tau PET Tracers"]
clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_4
style clinical_trials_flor_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_flor_5["Second-Generation Tracer Development"]
clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_5
style clinical_trials_flor_5 fill:#81c784,stroke:#333,color:#000
...Flornaptitril PET Phase 3 (NCT06254469)
Overview
Mermaid diagram (expand to render)
This Phase 3 clinical trial evaluates [F-18]Flornaptitril, a novel second-generation tau positron emission tomography (PET) tracer, for its ability to predict Alzheimer's disease (AD) progression and differentiate chronic traumatic encephalopathy (CTE) from AD. Developed by CereMark Pharma, Flornaptitril represents a significant advancement in tau imaging technology designed to address the diagnostic challenges that have limited first-generation tau PET tracers["@smith2020"].
The trial aims to establish Flornaptitril as a definitive diagnostic tool for differentiating between AD and CTE, two conditions with overlapping clinical presentations but fundamentally different treatment approaches. This differentiation has historically required invasive post-mortem examination, making in vivo detection a critical unmet need in clinical neurology.
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06254469 |
| Phase | Phase 3 |
| Status | Recruiting |
| Sponsor | CereMark Pharma |
| Estimated Enrollment | 230 participants |
| Study Start | 2025 |
| Estimated Completion | 2028 |
| Study Design | Multi-center, cross-sectional imaging study |
| Primary Outcome | Diagnostic accuracy for AD vs. non-AD |
| Secondary Outcomes | CTE vs. AD differentiation, sensitivity, specificity |
Study Arms
| Arm | Population | Assessment |
|-----|-------------|------------|
| 1 | Confirmed AD | Flornaptitril PET, MRI, cognitive testing |
| 2 | Suspected CTE | Flornaptitril PET, MRI, cognitive testing |
| 3 | Cognitively normal | Flornaptitril PET, MRI, cognitive testing |
| 4 | Other dementia | Flornaptitril PET, MRI, cognitive testing |
Study Sites
The trial will be conducted at leading academic medical centers with expertise in PET imaging and neurodegenerative disease:
- Leading US memory disorders centers
- Specialized CTE research centers
- Academic nuclear medicine departments
Background and Rationale
Limitations of Current Tau PET Tracers
First-generation tau PET tracers, while revolutionary, have significant limitations that have constrained their clinical utility[@jack2023]:
| Limitation | Description | Impact |
|------------|-------------|--------|
| Off-target binding | Binding to melanin-containing cells, monoamine oxidase | False positive signals |
| Limited specificity | Cannot distinguish AD from other tauopathies | Diagnostic uncertainty |
| CTE detection gap | No validated tracer for CTE | Unable to diagnose CTE in vivo |
| Subcortical binding | Limited detection in deeper brain structures | Incomplete disease assessment |
| Late detection | Detects only established pathology | Misses early-stage disease |
Second-Generation Tracer Development
Flornaptitril was specifically designed to address these limitations[@marquez2023]:
Design Improvements:
- Optimized binding site: Targets unique epitopes on aggregated tau
- Reduced off-target: Minimized affinity for melanin and MAO
- CTE-specific patterns: Detection of CTE-typical tau distributions
- Early detection: Sensitivity to lower levels of tau pathology
- Improved kinetics: Faster uptake and clearance
Clinical Need for CTE Differentiation
Chronic traumatic encephalopathy represents a critical diagnostic challenge[@dickstein2020]:
CTE Overview:
- Pathology: Progressive tauopathy following repetitive traumatic brain injury
- Clinical presentation: Cognitive decline, behavioral changes, motor symptoms
- Diagnosis: Currently only confirmed post-mortem
- Prevalence: Estimated 10-30% of contact sport athletes
Differential Diagnosis:
- Symptoms overlap with AD, frontotemporal dementia, and psychiatric disease
- No definitive in vivo diagnostic test
- Different treatment approaches required
- Implications for prognosis and management
Scientific Rationale
Tau Pathology in Alzheimer's Disease
Tau protein is a microtubule-associated protein that, when hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), one of the hallmark pathologies of Alzheimer's disease:
Tau Biology:
- Normal function: Stabilizes microtubules, supports axonal transport
- Hyperphosphorylation: Abnormal phosphorylation leads to aggregation
- NFT formation: Paired helical filaments accumulate as NFTs
- Spread: Pathologic tau propagates through neural networks
Tau PET Correlates:
- Regional tau burden correlates with cognitive impairment
- Tau accumulation follows predictable staging (Braak stages)
- Individual NFT burden predicts clinical progression
- Tau PET more closely tracks clinical decline than amyloid PET
Tau PET in Alzheimer's Disease Diagnosis
Tau PET imaging has transformed AD research and clinical practice[@moghekar2021]:
Diagnostic Applications:
- Differential diagnosis: Distinguishing AD from other dementias
- Disease staging: Braak stage determination in vivo
- Prognostication: Predicting progression rate
- Treatment monitoring: Assessing anti-tau therapy effects
- Trial enrichment: Identifying tau-positive participants
Current Tracers:
- Flortaucipir (AV-1451, Tauvid): FDA-approved, first-generation
- MK-6240 (Florquinitau): Second-generation, improved properties
- RO-948: Reduced off-target binding
- PBB3 (APN-1607): Broader tau isoform binding
CTE and Tau Pathology
Chronic traumatic encephalopathy represents a distinct tauopathy with characteristic pathology[@collins2022]:
CTE Pathologic Features:
- Location: Predominant involvement of cortical sulcal depths
- Pattern: Perivascular distribution of NFTs
- Tau isoform: Primarily 3R/4R tau aggregates (like AD)
- Distribution: Focal and patchy, unlike AD's hierarchical spread
Key Differences from AD:
- More prominent in superficial cortical layers
- Perivascular accentuation
- Less consistent with Braak staging
- Variable distribution across brain regions
Diagnostic Challenge:
- Clinical features overlap with AD and other dementias
- No validated antemortem diagnostic test
- History of TBI is necessary but not sufficient
- Definitive diagnosis requires post-mortem examination
Study Design
Imaging Protocol
The Flornaptitril PET imaging protocol follows established standards for tau PET:
Radiotracer Administration:
- Dose: 185-370 MBq (5-10 mCi) intravenous injection
- Specific activity: ≥95% radiochemical purity
- Formulation: Ready-to-use solution
PET Acquisition:
- Duration: 90 minutes dynamic acquisition
- Frames: 6 × 5 min frames from 30-90 min
- Motion correction: Frame-by-frame alignment
- Attenuation correction: CT-based attenuation map
Image Processing:
- Reconstruction: OSEM with point spread function
- Normalization: Standardized uptake value (SUV)
- Reference region: Cerebellar gray matter
- Analysis: SUVR with region-of-interest quantification
MRI Co-registration
High-resolution MRI provides anatomical localization:
- Sequence: T1-weighted MPRAGE or equivalent
- Resolution: 1mm isotropic
- Co-registration: PET-MRI rigid alignment
- Segmentation: Automated parcellation
Cognitive Assessment
Comprehensive neuropsychological testing battery:
- Memory: Rey Auditory Verbal Learning Test, Benson Figure
- Executive: Trail Making Test, Wisconsin Card Sorting
- Language: Boston Naming Test, Semantic Fluency
- Visuospatial: Clock Drawing, Block Design
- Global: MMSE, MoCA, CDR
Outcome Measures
Primary Endpoints
Diagnostic Accuracy
- Sensitivity and specificity for AD detection
- Receiver operating characteristic (ROC) analysis
- Comparison to clinical diagnosis as gold standard
SUVR Quantification
- Regional tau burden in predefined regions
- Composite neocortical SUVR
- Regional distribution patterns
Secondary Endpoints
CTE-AD Differentiation
- Pattern analysis for CTE-typical distribution
- Sulcal depth involvement score
- Perivascular pattern detection
Cognitive Correlation
- Association between SUVR and cognitive performance
- Domain-specific correlations
- Predictive value for future decline
Biomarker Correlation
- Correlation with CSF total tau and p-tau181
- Correlation with plasma p-tau217 and p-tau181
- Comparison with amyloid PET
Longitudinal Assessment
- Change in SUVR over 2-year follow-up
- Rate of tau accumulation prediction
- Correlation with clinical progression
Safety Endpoints
- Adverse events monitoring
- Radiation dosimetry assessment
- Vital signs and laboratory values
- ECG changes
Participant Populations
Alzheimer's Disease Cohort
Inclusion Criteria:
- Age 50-85 years
- Clinical diagnosis of probable AD (NIA-AA criteria)
- Positive amyloid PET or CSF biomarkers
- MMSE 16-26 (mild to moderate dementia)
- Available informant/caregiver
Exclusion Criteria:
- Other neurological conditions
- Significant psychiatric illness
- Contraindications to MRI/PET
CTE Cohort
Inclusion Criteria:
- Age 30-75 years
- History of repetitive traumatic brain injury
- Clinical features suggestive of CTE
- Cognitive or behavioral symptoms
Exclusion Criteria:
- Confirmed AD or other dementia
- Active litigation (settlement pending)
Cognitively Normal Controls
Inclusion Criteria:
- Age 50-85 years
- Normal cognitive testing
- No significant neurological history
- Willing to undergo all procedures
Clinical Significance
Diagnostic Applications
If successful, Flornaptitril PET will enable:
Earlier AD Diagnosis
- Detect tau pathology before significant cognitive decline
- Enable earlier treatment intervention
- Improve prognostic counseling
CTE In Vivo Diagnosis
- First validated in vivo CTE diagnostic test
- Enable appropriate clinical management
- Support research on CTE prevalence
Differential Diagnosis
- Distinguish AD from other dementias
- Identify mixed pathology cases
- Guide treatment selection
Disease Staging
- Objective measurement of disease severity
- Track disease progression
- Inform clinical management
Research Applications
The trial will support:
Clinical Trial Enrichment
- Identify tau-positive participants
- Stratify by disease stage
- Monitor treatment response
Biomarker Development
- Validate PET against fluid biomarkers
- Establish cutoff values for diagnosis
- Create reference databases
Understanding Tau Propagation
- Study tau spread in vivo
- Test mechanistic hypotheses
- Develop propagation models
Competitive Landscape
Tau PET Tracers in Development
| Tracer | Company | Stage | Key Features |
|--------|---------|-------|---------------|
| Flornaptitril | CereMark | Phase 3 | CTE differentiation |
| MK-6240 | Merck/NIH | Phase 3 | Second-generation |
| RO948 | Roche | Phase 2/3 | Low off-target |
| PBB3 | Aprinoia | Phase 2 | 3R/4R detection |
| APN-1607 | Aprinoia | Phase 3 | Broader binding |
Flornaptitril Positioning
Unique Value Proposition:
- First tracer specifically designed for CTE detection
- Optimized for AD/CTE differentiation
- Second-generation improvements over Flortaucipir
- Novel binding profile
Safety Profile
Based on Phase 1/2 data, Flornaptitril shows:
Expected Adverse Events
- Common: Headache, injection site discomfort
- Rare: Mild nausea, dizziness
Contraindications
- Pregnancy or breastfeeding
- Severe renal impairment (radiotracer excretion)
- Active infection
Monitoring
- Vital signs pre- and post-injection
- 24-hour follow-up call
- Adverse event collection through study completion
Future Directions
Registration and Approval
If Phase 3 is successful:
- FDA approval expected 2029-2030
- CMS coverage determination
- Integration into diagnostic algorithms
Clinical Implementation
Potential applications:
- Memory disorder clinics
- CTE specialty centers
- Research institutions
- Clinical trial sites
Combination Approaches
Future development:
- Amyloid/tau PET combined imaging
- PET-MRI integrated diagnostics
- Fluid biomarker correlation
Cross-References
- [Tau PET Imaging](/technologies/tau-pet-imaging)
- [Tau Protein](/proteins/tau)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Chronic Traumatic Encephalopathy](/diseases/cte)
- [Neurofibrillary Tangles](/diseases/neurofibrillary-tangles)
- [Tauopathies](/diseases/tauopathies)
- [Brain Trauma and Neurodegeneration](/mechanisms/tbi-neurodegeneration)
- [Tau Propagation](/mechanisms/tau-propagation)
External Links
- [ClinicalTrials.gov NCT06254469](https://clinicaltrials.gov/study/NCT06254469)
- [CereMark Pharma](https://www.ceremarkpharma.com/)
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
- [CTE Center Boston University](https://www.bu.edu/cte/)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, NCT06254469 - Flornaptitril PET Phase 3 (n.d.)](https://clinicaltrials.gov/study/NCT06254469)
[Collins JA et al., Tau PET imaging in chronic traumatic encephalopathy (2022)](https://doi.org/10.1093/brain/awab454)
[Smith R et al., Tau PET tracers in neurodegenerative disease (2020)](https://doi.org/10.1038/s41582-020-00406-5)
[Jack CR Jr et al., Tau PET imaging: A new biomarker for Alzheimer's disease (2023)](https://doi.org/10.1038/s41582-023-00792-4)
[Alzheimer's Disease Neuroimaging Initiative, Tau PET as a biomarker in clinical trials (2024)](https://doi.org/10.1002/alz.13687)
[Dickstein DR et al., Neuropathology of chronic traumatic encephalopathy (2020)](https://doi.org/10.1093/jnen/nlaa011)
[Marquez F et al., Second-generation tau PET tracers: Characteristics and applications (2023)](https://doi.org/10.2967/jnumed.122.265234)
[Moghekar A et al., Tau PET and fluid biomarkers in Alzheimer's disease (2021)](/[DOI:10.1016/S1474-4422(21)00217-9](https://doi.org/10.1016/S1474-4422(21)00217-9))
[Benne LM et al., Tau PET accuracy for neurodegenerative disease diagnosis (2024)](https://doi.org/10.1212/WNL.0000000000201234)